Compare · ARGX vs SRRK
ARGX vs SRRK
Side-by-side comparison of argenx SE (ARGX) and Scholar Rock Holding Corporation (SRRK): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ARGX and SRRK operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- ARGX is the larger of the two at $54.76B, about 10.4x SRRK ($5.25B).
- Over the past year, ARGX is up 52.1% and SRRK is up 31.0% - ARGX leads by 21.1 points.
- SRRK has been more active in the news (10 items in the past 4 weeks vs 5 for ARGX).
- ARGX has more recent analyst coverage (25 ratings vs 19 for SRRK).
- Company
- argenx SE
- Scholar Rock Holding Corporation
- Price
- $887.74+0.58%
- $44.70+2.07%
- Market cap
- $54.76B
- $5.25B
- 1M return
- +13.52%
- -7.71%
- 1Y return
- +52.11%
- +31.03%
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2017
- 2018
- News (4w)
- 5
- 10
- Recent ratings
- 25
- 19
argenx SE
argenx SE, a clinical-stage biotechnology company, focuses on developing antibody-based therapies for the treatment of autoimmune diseases, hematology, and cancer. It is developing its lead product candidate, efgartigimod, for the treatment of patients with myasthenia gravis; immune thrombocytopenia in Phase III; pemphigus vulgaris in Phase III; chronic inflammatory demyelinating polyneuropathy in Phase III; and ENHANZE SC in pre-clinical stages. The company is also developing cusatuzumab in Phase II clinical stage in hematological cancer indications; ARGX-117 in phase I clinical trial with therapeutic potential in both orphan and large autoimmune inflammatory diseases; and preclinical products, including ARGX-118 for airway inflammation. Its partnered product candidates include ARGX-112 for treating skin inflammation, ARGX-116 for the treatment of dyslipidemia, and ARGX-115 for cancer immunotherapy, which are in Phase I clinical stages; and ARGX-114 for treating fibrosisand ARGX-119 for treating neuromuscular indications, which are in preclinical stage. The company has strategic partnership with AbbVie S.Ã.R.L. and LEO Pharma A/S; and collaboration agreement with Cilag GmbH International, Staten Biotechnology B.V., and Shire International GmbH. argenx SE was incorporated in 2008 and is based in Breda, the Netherlands.
Scholar Rock Holding Corporation
Scholar Rock Holding Corporation, a clinical-stage biopharmaceutical company, focuses on the discovery and development of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, a novel inhibitor of the activation of latent myostatin that has completed the Phase II clinical trials for the treatment of spinal muscular atrophy; and SRK-181, which is in Phase I clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies. It is also developing a pipeline of novel product candidates with potential to transform the lives of patients suffering from a range of serious diseases, including neuromuscular disorders, cancer, and fibrosis. The company has a collaboration agreement with Gilead Sciences, Inc. to discover and develop specific inhibitors of transforming growth factor beta activation for the treatment of fibrotic diseases. Scholar Rock Holding Corporation was founded in 2012 and is headquartered in Cambridge, Massachusetts.
Latest ARGX
- SEC Form 6-K filed by argenx SE
- argenx Presents New Efgartigimod Data Showing Long-Term Sustained Patient Benefit in Myositis and Sjogren's Disease at EULAR 2026
- argenx to Host Myositis R&D Webinar on June 23, 2026
- argenx to Present at Upcoming Investor Conferences
- The Biology Came First.
- SEC Form 6-K filed by argenx SE
- argenx Announces U.S. FDA Approval Expanding VYVGART and VYVGART Hytrulo for Use in All Adult Patients Living with gMG
- SEC Form 6-K filed by argenx SE
- argenx Reports First Quarter 2026 Financial Results and Provides Business Update
- argenx to Present at BofA Securities 2026 Health Care Conference
Latest SRRK
- Director Flier Jeffrey S. was granted 6,839 shares, increasing direct ownership by 28% to 30,909 units (SEC Form 4)
- Director Reed Joshua was granted 6,839 shares, increasing direct ownership by 43% to 22,571 units (SEC Form 4)
- Director Brudnick Richard was granted 6,839 shares, increasing direct ownership by 45% to 21,896 units (SEC Form 4)
- Director Burow Kristina was granted 6,839 shares, increasing direct ownership by 6% to 117,710 units (SEC Form 4)
- Director Gilman Michael was granted 6,839 shares, increasing direct ownership by 12% to 62,055 units (SEC Form 4)
- Director Peng Katie was granted 6,839 shares, increasing direct ownership by 21% to 39,747 units (SEC Form 4)
- Director Akkaraju Srinivas was granted 6,839 shares, increasing direct ownership by 32% to 27,971 units (SEC Form 4)
- Scholar Rock Holding Corporation filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders
- Scholar Rock to Present at the Goldman Sachs 47th Annual Global Healthcare Conference
- Scholar Rock to Present at the 2026 Jefferies Global Healthcare Conference